Demand and supply, rationing of effective medicines, issues about prices and technology assessment models have to be addressed in a new way. New developments, increasing burden due to non-communicable diseases in an aging population, increasing health care costs are all phenomena that increase the risk of unjustified rationing in health care.

Therefore, new answers and models have to be developed in order to guarantee a maximum benefit for populations.

Pharmaprofiling offers a basis for the communication of new developments and models.